5 news items
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
VIR
29 May 24
or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
VIR
22 May 24
development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR
21 May 24
disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
as of December 31, 2022. The decrease was primarily due to payout of daily operations and research and development activities
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results
- Prev
- 1
- Next